VERV – Verve Therapeutics Inc

Verve Therapeutics, Inc. 是一家基因药物公司,开创了一种治疗心血管疾病或CVD的新方法,将治疗从慢性管理转变为单程基因编辑药物。他们认为,单疗程治疗可以为患有动脉粥样硬化性心血管疾病或ASCVD或有患动脉粥样硬化性心血管疾病风险的患者提供终生持续的显着健康益处。于2018年3月9日成立为特拉华州公司。

中文介绍: https://xueqiu.com/S/VERV

Verve Therapeutics Inc is a genetic medicines company pioneering the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. Its initial programs focus on PCSK9 and ANGPTL3, two genes that regulate levels of blood lipids. The company is developing these gene-editing treatments for patients with familial hypercholesterolemia, a genetic disease that causes life-long severely elevated blood cholesterol.

英文介绍: https://www.morningstar.com/stocks/xnas/verv/quote

主题测试文章,只做测试使用。发布者:star,转转请注明出处:http://wallstreetgm.com/verv-verve-therapeutics-inc/

发表评论

您的电子邮箱地址不会被公开。 必填项已用*标注